Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants with 3 expected upcoming patent grants in May.
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
Second United States Patent Granted For Small Pharma’s Psychedelics Portfolio
Brings total to twelve granted patents across the Company’s full portfolio.
Canadian Patent Grant Strengthens Small Pharma’s International Position
Further Composition of Matter protection for SPL028.
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy with Injectable Formulation
U.S. Patent Grant To Strengthen Small Pharma’s Dmt Patent Strategy With Injectable Formulation.
Small Pharma Reports Fiscal First Quarter 2023 Highlights
Progress continues with multiple trials expected to enter clinic later this year.
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022
Small Pharma reports highlights for the fiscal year ended February 2022.
Small Pharma Shares Business Update Ahead of Annual Financial Results
Small Pharma shares business update ahead of annual financial results, including a new COO appointment.
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Small Pharma expands its commercial portfolio with progress of two new trials.
European Patent Grant Strengthens Small Pharma’s Ketamine-based Patent Portfolio For The Treatment Of Depressive Disorders
Patent grant strengthens Small Pharma's portfolio for treatment for depressive disorders.